Literature DB >> 4809463

Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

L Milas, N Hunter, K Mason, H R Withers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4809463

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  32 in total

1.  Enhancement of lung colony formation by admixing irradiated with viable tumor cells: dependence on host status.

Authors:  L Milas; M Iwakawa; N Hunter
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

2.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Enhancement by misonidazole of metastatic tumor nodule formation in the lungs of mice.

Authors:  L Milas; N Daly; N Hunter; R Meoz; L J Peters
Journal:  Clin Exp Metastasis       Date:  1983 Jan-Mar       Impact factor: 5.150

4.  Increase in radiosensitivity of lung micrometastases by hyperbaric oxygen.

Authors:  L Milas; N M Hunter; H Ito; W A Brock; L J Peters
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

5.  Growth of metastases of the mouse adenocarcinoma EO 771: an allometric relationship between growth of the primary tumors and their metastases.

Authors:  I D Bassukas; B Maurer-Schultze
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

6.  The comparative effectiveness of rabbit anti-mouse thymocyte sera in potentiating the survival of mouse skin or tumour allografts made across the H-2 barrier.

Authors:  T Lai; M O Symes
Journal:  Immunology       Date:  1976-07       Impact factor: 7.397

7.  Behavioral characteristics of a mouse model of cancer pain.

Authors:  Bae Hwan Lee; Jinsil Seong; Un Jeng Kim; Ran Won; Jiyoung Kim
Journal:  Yonsei Med J       Date:  2005-04-30       Impact factor: 2.759

8.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

9.  Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.

Authors:  G Lopez-Berestein; L Milas; N Hunter; K Mehta; E M Hersh; C G Kurahara; M Vandupas; D A Eppstein
Journal:  Clin Exp Metastasis       Date:  1984 Apr-Jun       Impact factor: 5.150

10.  Canine migration inhibitory factor: effect of Corynebacterium parvum administration.

Authors:  M S Pineiro; C A Bowles; E C Cutchins; M I Bull
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.